Review of Efficacy and Safety of Semaglutide in the Management of Obesity
10.24304/kjcp.2024.34.1.1
- Author:
Seunghoon HAN
1
;
Tae Eun PARK
Author Information
1. College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea
- Publication Type:Review Article
- From:Korean Journal of Clinical Pharmacy
2024;34(1):1-20
- CountryRepublic of Korea
- Language:English
-
Abstract:
This review examines the pivotal clinical trials that evaluated the efficacy and safety of semaglutide, a glucagon-like peptide-1(GLP-1) receptor agonist, in the management of obesity. The reported findings underscore significant and sustained weight lossachieved with semaglutide in diverse patient groups, although gastrointestinal disorders occurred frequently, leading to therapy discontinuation. Overall, the studies demonstrated the potential of semaglutide as a therapeutic option not only for type 2 diabe-tes but also for obesity. The treatment landscape in obesity is evolving, as reflected in changing regulatory approvals and clinicalguidelines, suggesting a paradigm shift toward personalized approaches in this chronic disease states to achieve optimal treatment outcomes for patients.
